Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis
BackgroundWe performed a network meta-analysis of phase III trials to compare the efficacy and safety of first-line regimens for patients with advanced esophageal squamous cell carcinoma (ESCC).MethodsA systematic review and Bayesian network meta-analysis were conducted by retrieving relevant litera...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1369848/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850194253320290304 |
|---|---|
| author | Chenglong Wang Chenglong Wang Tongze Cai Tongze Cai Jiangcun Wei Ying Huang Lin Xiao Tong Li Tong Li Zujie Qin Zujie Qin |
| author_facet | Chenglong Wang Chenglong Wang Tongze Cai Tongze Cai Jiangcun Wei Ying Huang Lin Xiao Tong Li Tong Li Zujie Qin Zujie Qin |
| author_sort | Chenglong Wang |
| collection | DOAJ |
| description | BackgroundWe performed a network meta-analysis of phase III trials to compare the efficacy and safety of first-line regimens for patients with advanced esophageal squamous cell carcinoma (ESCC).MethodsA systematic review and Bayesian network meta-analysis were conducted by retrieving relevant literature from PubMed, Embase, the Cochrane Library, and the Web of Science. We included published sources of randomized clinical trials comparing immunotherapy combinations for treating advanced ESCC.ResultsWe analyzed seven studies involving eight immunotherapy combinations and 4688 patients. For patients without programmed death-ligand 1 (PD-L1) selection, it was found that the combination of toripalimab and chemotherapy provided better overall survival than chemotherapy alone (hazard ratio = 0.58, 95% confidence interval (CI) 0.43-0.78). Compared with chemotherapy alone, Sintilimab or camrelizumab plus chemotherapy seemed to achieve the best progression-free survival (hazard ratio = 0.56, 95% CI 0.46-0.68). Nivolumab plus chemotherapy appeared to provide the best objective response rate, with significant differences versus chemotherapy alone (odds ratio = 0.49, 95% CI 0.38-0.64). Nivolumab plus ipilimumab resulted in a relatively lower incidence of adverse events of grade ≥3 than other regimens.ConclusionsThe combination of immune checkpoint inhibitors (ICIs) with chemotherapy provided a high probability of more effective treatment in comparison with chemotherapy alone for patients with advanced ESCC. Toripalimab and sintilimab plus chemotherapy were ranked as providing the highest OS and PFS benefit in the first-line setting, respectively. |
| format | Article |
| id | doaj-art-32afb463b1674206800d9652b2c5a47c |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-32afb463b1674206800d9652b2c5a47c2025-08-20T02:14:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-11-011410.3389/fonc.2024.13698481369848Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysisChenglong Wang0Chenglong Wang1Tongze Cai2Tongze Cai3Jiangcun Wei4Ying Huang5Lin Xiao6Tong Li7Tong Li8Zujie Qin9Zujie Qin10Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, ChinaGraduate School, Guangxi University of Chinese Medicine, Nanning, ChinaGuangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, ChinaGraduate School, Guangxi University of Chinese Medicine, Nanning, ChinaGuangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, ChinaGuangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, ChinaGuangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, ChinaGuangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, ChinaGraduate School, Guangxi University of Chinese Medicine, Nanning, ChinaGuangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, ChinaGraduate School, Guangxi University of Chinese Medicine, Nanning, ChinaBackgroundWe performed a network meta-analysis of phase III trials to compare the efficacy and safety of first-line regimens for patients with advanced esophageal squamous cell carcinoma (ESCC).MethodsA systematic review and Bayesian network meta-analysis were conducted by retrieving relevant literature from PubMed, Embase, the Cochrane Library, and the Web of Science. We included published sources of randomized clinical trials comparing immunotherapy combinations for treating advanced ESCC.ResultsWe analyzed seven studies involving eight immunotherapy combinations and 4688 patients. For patients without programmed death-ligand 1 (PD-L1) selection, it was found that the combination of toripalimab and chemotherapy provided better overall survival than chemotherapy alone (hazard ratio = 0.58, 95% confidence interval (CI) 0.43-0.78). Compared with chemotherapy alone, Sintilimab or camrelizumab plus chemotherapy seemed to achieve the best progression-free survival (hazard ratio = 0.56, 95% CI 0.46-0.68). Nivolumab plus chemotherapy appeared to provide the best objective response rate, with significant differences versus chemotherapy alone (odds ratio = 0.49, 95% CI 0.38-0.64). Nivolumab plus ipilimumab resulted in a relatively lower incidence of adverse events of grade ≥3 than other regimens.ConclusionsThe combination of immune checkpoint inhibitors (ICIs) with chemotherapy provided a high probability of more effective treatment in comparison with chemotherapy alone for patients with advanced ESCC. Toripalimab and sintilimab plus chemotherapy were ranked as providing the highest OS and PFS benefit in the first-line setting, respectively.https://www.frontiersin.org/articles/10.3389/fonc.2024.1369848/fullnetwork meta-analysisfirst-line immune checkpoint inhibitor combination therapiesadvanced esophageal squamous cell carcinomaefficacysafety |
| spellingShingle | Chenglong Wang Chenglong Wang Tongze Cai Tongze Cai Jiangcun Wei Ying Huang Lin Xiao Tong Li Tong Li Zujie Qin Zujie Qin Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis Frontiers in Oncology network meta-analysis first-line immune checkpoint inhibitor combination therapies advanced esophageal squamous cell carcinoma efficacy safety |
| title | Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis |
| title_full | Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis |
| title_fullStr | Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis |
| title_full_unstemmed | Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis |
| title_short | Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis |
| title_sort | efficacy and safety of first line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma a network meta analysis |
| topic | network meta-analysis first-line immune checkpoint inhibitor combination therapies advanced esophageal squamous cell carcinoma efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1369848/full |
| work_keys_str_mv | AT chenglongwang efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT chenglongwang efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT tongzecai efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT tongzecai efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT jiangcunwei efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT yinghuang efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT linxiao efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT tongli efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT tongli efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT zujieqin efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis AT zujieqin efficacyandsafetyoffirstlineimmunecheckpointinhibitorcombinationtherapiesinpatientswithadvancedesophagealsquamouscellcarcinomaanetworkmetaanalysis |